Business
Director/PDMR Shareholding
Director/PDMR Shareholding.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 1058O\n Futura Medical PLC\n 05 October 2021\n \n \n \n \n Directors' / PDMR Dealing and Grant of Options\n \n 5 October 2021\n \n Futura Medical plc (AIM: FUM) (\"Futura\" or the \"Company\"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology currently focused on sexual health and pain, today announces that on 4 October 2021 it made its annual grant of options over a total of 1,654,800 ordinary shares of 0.2p each in the Company (\"Ordinary Shares\") to employees and Directors, of which 858,000 options were granted to Directors and PDMRs as detailed below.\n \n \n \n \n \n \n Director\n \n \n \n \n Number\nof options\ngranted\n \n \n \n \n Exercise\nprice\n \n \n \n \n Exercise period\n \n \n \n \n Total number\nof options\nheld following\nnotification\n \n \n \n \n Total number\nof Ordinary\nShares held\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n J H Barder\n \n \n \n \n 330,000\n \n \n \n \n 37.9p\n \n \n \n \n 1 Oct 2023 - 30 Sep 2028\n \n \n \n \n 1,880,000\n \n \n \n \n 1,210,972\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n A Hildreth\n \n \n \n \n 264,000\n \n \n \n \n 37.9p\n \n \n \n \n 1 Oct 2023 - 30 Sept 2028\n \n \n \n \n 904,000\n \n \n \n \n 142,857\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n K W James\n \n \n \n \n 264,000\n \n \n \n \n 37.9p\n \n \n \n \n 1 Oct 2023 - 30 Sept 2028\n \n \n \n \n 1,304,000\n \n \n \n \n 299,581\n \n \n \n \n \n \n \n \n \n Of the total 1,654,800 options, 1,155,122 were granted under the Futura Medical plc Enterprise Management Incentive Scheme, and 499,678 were granted under the unapproved scheme.\n \n \n The main vesting condition of the options is that the Director/PDMR/employee remains employed with the Company as at the date of exercise. Further disclosures are contained in the tables below. \n \n \n ENDS\n \n \n \n \n For further information please contact:\n \n Futura Medical plc \nJames Barder, Chief Executive\nAngela Hildreth, Finance Director and COO\n Email: [email protected]\nTel: +44 (0) 1...